attem / Shutterstock.com
Pharmaceutical company Gilead Sciences has settled its patent dispute with Indian-based rival Natco Pharma over an attempt to market a generic version of its Tamiflu (oseltamivir phosphate) product.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead; Natco Pharma; Tamiflu; ANDA; US FDA; US Court of Appeals for the Federal Circuit; US District Court for the District of New Jersey
